Daiken Biomedical CoTPE:7780 +1.66%23 ROE % is 9.24% as of Dec. 2025, which is 65% below its 10-year median of 26.68. GuruFocus rates TPE:7780 with a GF Score™ of 23/100. The stock has 6 warning signs investors should review. Among 1,914 Consumer Packaged Goods companies, Daiken Biomedical Co ranks better than 68.6% on this metric.
The historical rank and industry rank for Daiken Biomedical Co's ROE % or its related term are showing as below:
TPE:7780'
s ROE % Range Over the Past 10 Years
Min: 10.01 Med: 26.68 Max: 67.55
Current: 11.71
During the past 4 years, Daiken Biomedical Co's highest ROE % was 67.55%. The lowest was 10.01%. And the median was 26.68%.
TPE:7780's ROE % is ranked better than 68.6% of 1914
companies
in the Consumer Packaged Goods industry
Industry Median: 6.685
vs TPE:7780: 11.71
Daiken Biomedical Co (TPE:7780) ROE % Explanation
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
Note:
The net income data used here is four times the quarterly (Dec. 2025) net income data. The Revenue data used here is four times the quarterly (Dec. 2025) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net Income is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Packaged Foods subindustry, Daiken Biomedical Co's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Daiken Biomedical Co ROE % vs Consumer Packaged Goods Industry
For the Consumer Packaged Goods industry and Consumer Defensive sector, Daiken Biomedical Co's ROE % distribution charts can be found below:
* The bar in red indicates where Daiken Biomedical Co's ROE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Dec. 2025) net income data.
ROE % is displayed in the 30-year financial page.
Daiken Biomedical Co (TPE:7780) has a ROE % of 9.24% as of Dec. 2025. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Daiken Biomedical Co and its competitors. This is 65% below median its historical median of 26.68. Over the past decade, Daiken Biomedical Co's ROE % has ranged from 10.01 to 67.55. According to the industry distribution chart, Daiken Biomedical Co ranks #601 out of 1914 companies in the Consumer Packaged Goods industry, placing it in the top 31.4%.
Is Daiken Biomedical Co's ROE % too high?
Daiken Biomedical Co's current ROE % of 9.24% is 65% below median its 10-year median of 26.68. Over the past 10 years, this metric has ranged from a low of 10.01 to a high of 67.55. The Consumer Packaged Goods industry median ROE % is 6.69. Daiken Biomedical Co's value of 9.24% is 38.2% above this industry median. Based on the distribution chart, Daiken Biomedical Co ranks #601 out of 1914 companies in the Consumer Packaged Goods industry, which is above the industry midpoint. Overall, Daiken Biomedical Co has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does Daiken Biomedical Co's ROE % compare to KHC and GIS?
According to the Consumer Packaged Goods industry distribution chart, Daiken Biomedical Co ranks #601 out of 1914 companies for ROE %. This puts Daiken Biomedical Co in the upper half of its industry. The industry median ROE % is 6.69. Daiken Biomedical Co's value of 9.24% is 38.2% above this benchmark. Historically, Daiken Biomedical Co's own ROE % has ranged from 10.01 to 67.55 over the past decade. While the company's 10-year median is 26.68 vs. the industry median of 6.69, Daiken Biomedical Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Consumer Packaged Goods company?
The median ROE % among Consumer Packaged Goods companies is 6.69, based on 1,914 companies in the industry. Companies in the top quartile (top 25%) have a ROE % significantly above this median, while those in the bottom quartile fall well below. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Daiken Biomedical Co's current ROE % of 9.24% is 38.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Daiken Biomedical Co and its competitors. For the Consumer Packaged Goods industry, the median ROE % is 6.69 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Daiken Biomedical Co's current ROE % is 9.24%, which is 65% below median its own 10-year median of 26.68. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Daiken Biomedical Co stock overvalued right now?
Daiken Biomedical Co (TPE:7780) has a current ROE % of 9.24%. The current ROE % is 9.24%, which is 65% below median its 10-year median of 26.68 and 38.2% above the Consumer Packaged Goods industry median of 6.69. Daiken Biomedical Co's overall GF Score™ is 23/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For Daiken Biomedical Co (TPE:7780), the current ROE % is 9.24% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Daiken Biomedical Co Ltd is engaged in Research, development, and sales of health food. Its products include fish oil capsules, collagen powder, collagen drinks, natto capsules, and mint leaf capsules. The companies reportable operating segment consists solely of the e-commerce division.
23GF Score
Get the complete analysis for TPE:7780
ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:7780 has been successfully added to your 
